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Spiromax® inhaler was also investigated. Methods: The eligible adult patient 
population was based on current confirmed UK asthma and COPD diagnosis rates, 
with the proportion receiving FDCs based on market research data.  Costs of FDCs 
and scheduled and unscheduled healthcare events were taken from publicly avail-
able UK sources.  Frequency of poor inhalation technique with the market-leading 
DPIs, and the associated increased risk of unscheduled healthcare events, were 
taken from a large (n=1,664) cross-sectional, Italian observational study, with the 
estimated reduction in the proportion of patients with poor inhalation technique 
with DuoResp® Spiromax® based on a conservative assumption. Results: The 
model estimated that 400,926 adult patients use Symbicort® Turbohaler® and 
357,008 Seretide® Accuhaler® annually and were therefore eligible for treatment 
with DuoResp® Spiromax®, with 174,403 and 123,168 of these exhibiting poor 
inhalation technique, respectively.  Assuming a hypothetical uptake of DuoResp® 
Spiromax® reaching 13% in year 4 and 5, and its current UK price, the model 
predicted drug cost savings totalling £65.57 million over five years.  Furthermore, 
64,845 unscheduled healthcare events could be avoided due to the predicted 
improvement in inhalation technique with DuoResp® Spiromax® compared with 
these DPIs, resulting in further savings of £4.78 million. ConClusions: DuoResp® 
Spiromax® is likely to offer budgetary savings compared with market-leading 
DPIs, with further cost savings potentially resulting from improved inhalation 
technique.
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objeCtives: To estimate and compare the use and frequency of medical resources 
needed in the treatment of exacerbation episodes in patients with COPD at out-
patient and inpatient care levels from a public Mexican institutional perspec-
tive, in this case insured patients from the “Instituto Mexicano del Seguro Social” 
(IMSS). Methods: From January to December 2013, a retrospective study was 
performed to estimate the direct medical costs of COPD exacerbations. The level 
of acuteness and treatment patterns used for the study where the same as those 
defined by the institution (IMSS guideline). Patient records were retrieved from 
the open institutional electronic databases for a 11822 COPD patients cohort. 
Exacerbation episodes were classified according to the guideline. Inpatient and 
outpatient care was the criteria for assessing the use and frequency of medical 
resources, including relevant outcomes as hospitalization, physician visits, inten-
sive care unit, surgery, medication use, clinical studies among others. Unitary costs 
were obtained from public tabulators (2014 IMSS). Mean frequency values were 
weighted with its corresponding costs. Results: In 2013, 16122 episodes of exac-
erbation were reported by the studied subjects. Patients over 45 years represented 
97% of all cases; being those over 65 years the most frequent (81%). A mean average 
of 5.6 days of inpatient care was founded at the study horizon. Yearly weighted 
cost of treatment for outpatient and inpatient care was US$8,630 and US$51,259 
respectively. A unitary item costs analysis from the inpatient versus the outpa-
tient treatment groups founded a significant increase in medication use (+83%), 
specialty visits (+100%), surgery (+100%) among other items. ConClusions: In 
the treatment of exacerbation episodes in patients with COPD, the aggregated 
cost per year of inpatient versus outpatient care was estimated to be 83% higher. 
Reducing the risk of exacerbation episodes with the right treatment choice would 
be relevant for Mexican institutions.
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health-caRe cOStS OF aSthma aRe lOweR uSIng mP29-02* VS. 
SequentIal SPRayS FOR alleRgIc RhInItIS
Harrow B.1, Sedaghat A.R.2, Munzel U.3, Tarr A.4, Gever L.1, Hofmeister J.1, Dufour R.4
1Meda Pharmaceuticals, Somerset, NJ, USA, 2Massachusetts Eye and Ear Infirmary and Harvard 
Medical School, Boston, MA, USA, 3MEDA Pharma GmbH & Co. KG, Bad Homburg, Germany, 
4Comprehensive Health Insights, Inc, Louisville, KY, USA
objeCtives: Allergic rhinitis (AR) affects 20% of the population, and 40% of these 
patients report a diagnosis of asthma. Previous work has shown that treatment of 
AR improves asthma control. The objective was to examine healthcare costs related 
to AR and asthma for patients either treated with MP29-02*, a novel intranasal for-
mulation of azelastine hydrochloride and fluticasone propionate in an advanced 
delivery system, or combination therapy with single ingredient intranasal antihis-
tamine (INA) and intranasal corticosteroid (INS) sprays. Methods: A retrospective 
analysis of medical and pharmacy claims of a commercially-insured U.S. popula-
tion was performed to evaluate differences in costs between two treatment groups 
(MP29-02* and INA/INS combination therapy). Medical and pharmacy claims occurring 
between 9/1/2011-3/31/2014 were used. Inclusion criteria included a diagnosis of rhi-
nitis (defined by ICD-9 472.0, 477.xx), at least 1 claim for a prescription intranasal spray 
(designated as the index date) during the identification period (9/1/2012—12/31/2013), 
12 months pre-index and 6-months post-index continuous enrollment, and no pre-
index claims for an intranasal spray. Patients diagnosed with asthma (493.xx) during 
the observation period were flagged. Inverse propensity score weighting adjustment 
was used to control for demographic, comorbidity, geographical and seasonal attrib-
utes. Adjusted mean AR-related and asthma-related costs for 6-months post-index 
were compared. Results: Total medical and pharmacy costs for the MP29-02* cohort 
(n= 810) are $2,782, statistically significant lower than for INA/INS cohort (n= 726) with 
$3,493 (P= .0074). For the sub-cohort with asthma, the MP29-02* cohort (n= 109) had 
lower asthma-related pharmacy costs ($247 vs. $796, P= .0193) and lower total asthma-
related costs ($565 vs. $1068, P= .0311) compared to the INA/INS asthmatic sub-cohort 
(n= 113). ConClusions: For individuals with asthma and rhinitis, MP29-02* is asso-
ciated with lower asthma-related costs compared to sequential INA/INS therapy in 
particular for pharmacy costs highlighting the economic impacts of formulation and 
delivery system in intranasal AR therapy. *Dymista
stay served to contribute to a 0.19% probability increase of 30-day readmissions 
(p< 0.001). ConClusions: Several comorbidities and a previous record of hospi-
talizations served as risk factors for 30-day readmissions. Patients with these risk 
factors are vulnerable and merit special attention.
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objeCtives: The societal economic burden of asthma was $56 billion (direct and 
indirect costs) in 2007. Inpatient costs represented 28%-43% of the total direct costs 
(excluding prescription costs). The objective of this study is to estimate the deter-
minants of 30-day hospital readmissions among patients with asthma. Methods: 
A cross-sectional analysis was conducted for patients with asthma (ICD 9 code 
493) among all age groups utilizing the 2012 Truven MarketScan dataset. Patients 
discharged to home or other facilities were included (un-weighted n= 16,390). 
A multivariable logit model was employed where the outcome variable was a 
dichotomous 30-day readmission (any caused readmission). The covariates 
included demographic characteristics, length of stay at index hospitalization, 
past healthcare utilizations, and comorbidities. Results: Among patients 
with asthma, the readmission rate within 30 days after the index hospitaliza-
tion discharge was 4.8%. Older groups were more likely to be readmitted than 
younger group (17-34 aged): Odds ratio (OR)= 1.59 (35-44 aged, p= 0.023), 1.61 (45-
54 aged, p= 0.012) and 1.71 (55-64 aged, p= 0.007). Patients with HMO, PPO and 
Comprehensive insurances were 72% more (OR= 1.72, p< 0.001), 31% less (OR= 0.69, 
p= 0.031) and 68% less (OR= 0.32, p< 0.001) likely to be readmitted than those with 
PPO, respectively. Patients discharged to other facilities were 388% (OR= 4.88, 
p< 0.001) more likely to be readmitted than those discharged to home. Patients 
with connective tissue disease were 63% (OR= 1.63, p= 0.007) more likely to be 
readmitted within 30 days than those without. In addition, an increase of hospi-
talization in the prior year contributed to a 1.36% probability increase of 30-day 
readmissions (p< 0.001). ConClusions: Patient groups vulnerable for 30-day 
readmissions after hospitalization were identified among patients with asthma. 
A comorbidity disease and a previous record of healthcare utilization were risk 
factors for 30-day readmission.
ReSPIRatORy-Related dISORdeRS – cost Studies
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objeCtives: To estimate annual drug wastage (drug that is discarded without being 
administered to a patient) and associated costs incurred by a typical hospital due to 
the use of multi-unit-dose packaged COPD treatment devices in patients admitted 
for acute chronic obstructive pulmonary disease (COPD) exacerbation. Methods: 
An economic model was built to evaluate the annual number of wasted doses and 
related costs associated with adult patients admitted to the hospital for an acute 
COPD exacerbation. Model inputs were based on a retrospective study of adults with 
COPD admitted to a university-affiliated hospital between January 2011 and June 2012 
(Sakaan, Am J Respir Crit Care Med. 2014). Wasted doses for the following comparators 
were assessed: albuterol, arformoterol, fluticasone, formoterol, ipratropium, tiotro-
pium, budesonide/formoterol, and fluticasone/salmeterol (all non-nebulized formu-
lations except arformoterol). Because arformoterol is available in a single-unit-dose 
package, no wastage was assumed. Pharmacy costs of wasted doses were calculated 
from number of doses wasted and publicly available wholesale acquisition cost per 
dose (Red Book™, 2014). Results: Based on a hospital with 500 COPD admissions 
per year, the estimated annual number of wasted doses was 18,045 (87%) at a cost of 
$69,103. Budesonide/formoterol, tiotropium, and fluticasone/salmeterol were most 
costly, representing an annual cost of $28,292, $17,686, and $17,366 in drug wastage, 
respectively. Arformoterol ($0), formoterol ($518), and fluticasone ($550) had the low-
est annual drug wastage costs. The highest drug wastage costs per patient were with 
fluticasone ($195) and budesonide/formoterol ($161), while the lowest drug wastage 
costs per patient were with arformoterol ($0) and albuterol ($17). ConClusions: For 
patients admitted to the hospital with a COPD exacerbation, the use of multi-unit-
dose packaged devices may result in significant costs due to drug wastage that could 
be avoided with use of single-unit-dose packaged devices.
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objeCtives: DuoResp® Spiromax® (budesonide + formoterol fumarate dihy-
drate) is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-
acting beta agonist (LABA) in a novel dry powder inhaler (DPI).  An economic 
model was developed to assess the budget impact of switching adult patients 
with persistent asthma and chronic obstructive pulmonary disease (COPD) from 
market-leading DPIs in the United Kingdom (UK)  - Symbicort® Turbohaler® and 
Seretide® Accuhaler®  - to DuoResp® Spiromax®.  The potential cost benefit 
of improved inhalation technique due to the innovative characteristics of the 
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objeCtives: To evaluate the patient characteristics and health care burden asso-
ciated with chronic obstructive pulmonary disease (COPD) in the U.S. Medicare 
population. Methods: COPD patients were identified (International Classification 
of Disease, 9th Revision, Clinical Modification [ICD-9-CM] codes: 491.xx, 492.xx and 
496.xx) using U.S. national Medicare claims from 01JAN2007 to 31DEC2010. The first 
diagnosis date was designated as the index date. Patients were required to: a) be age 
≥ 65 years on the index date; b) have continuous medical and pharmacy benefits for 12 
months pre-index date (baseline period); c) have continuous enrollment for 12 months 
post-index date (follow-up period), unless there was earlier evidence of death; and d) 
have no COPD diagnosis pre-index date. The outcomes of interest included medication 
use, including a long-acting beta agonist (LABA) or LABA/inhaled corticosteroid (ICS) 
combination, mortality and health care resource utilization and costs. Results: A 
total of 543,249 COPD patients were identified. Patients were, on average, age 78 years. 
Most patients were white (94%) and resided in the South U.S. region (41%). The average 
Charlson Comorbidity Index score was 3.23, and hypertension (67%), diabetes (28%), 
congestive heart failure (21%) and chronic pulmonary disease (20%) were the most 
frequently diagnosed comorbidities. A 13.82% mortality rate was observed during 
the first year of the follow-up period. Post-index LABA medications, including arfo-
moterol (0.55%), formoterol (0.25%) and salmeterol (0.32%) were prescribed to 1.10% 
of the population. Identified LABA/ICS combinations included budesonide/formoterol 
(1.97%) and fluticasone/salmeterol (10.02%). High health care resource utilization was 
encountered for Medicare carrier (99.40%), pharmacy (90.27%), outpatient (76.52%) 
and inpatient visits (48.83%). The main cost drivers were inpatient ($10,645), Medicare 
carrier ($4,888), outpatient ($3,322) and skilled nursing facility ($2,695) costs, resulting 
in $25,397 in total health care costs. ConClusions: U.S. Medicare patients have a 
high COPD-related health care burden.
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objeCtives: The aim of this study was to examine the association between 
inhaled bronchodilators and the utilization of healthcare services in newly-diag-
nosed COPD patients using a nationalwide health insurance administrative data-
bases. Methods: The Taiwan National Health Insurance Research Databases were 
used. Participants ≧ 40-years-old who had not been diagnosed with COPD between 
2006 and 2007 but were diagnosed and prescribed COPD medications in 2008 were 
recruited as newly diagnosed COPD patients. Patients were categorized into three 
groups depending on their medications use, an inhaled long-acting bronchodila-
tor (ILA-B), an inhaled short-acting bronchodilator (ISA-B) and an oral respiratory 
medication (ORM) group. The risk of COPD emergency department visits, hospi-
talization and healthcare costs were compared among cohorts during 1 year of 
follow-up. Results: A total of 13,181 newly-diagnosed COPD patients with a mean 
age of 65.2 years, among which 8,055 (60.7%) were men, were included in the study. 
ED visits and hospitalization were associated with ISA-B cohort, male gender, older 
age, copayment exemptions, tertiary healthcare institutions visits, non-pulmonary 
specialist physicians and higher comorbidities. Multivariate analysis showed that 
the ISA-B cohort was associated with more ED visits, recurrent ED visits, hospitaliza-
tions and rehospitalizations (adjusted ORs [95% confidence intervals] = 5.06 [3.46, 
7.41], 3.98 [2.08, 7.58], 1.59 [1.18, 2.21], and 1.42 [1.19, 2.18], respectively) compared 
with the ILA-B cohort. The ILA-B cohort incurred significantly higher adjusted phar-
macy costs per patient per year by $165 (95% CI: $97, $233; P< 0.001) vs the ISA-B 
cohort, whereas adjusted medical costs per patient per year were significantly 
lower in the ILA-B cohort vs the ISA-B cohort ($348 vs $564; P< 0.001). The total 
yearly adjusted costs per patient, as a result, did not differ significantly between 
this two cohorts. ConClusions: Initiation of Inhaled long-acting bronchodilator 
treatment was associated with better clinical and economic outcomes compared 
to inhaled short-acting bronchodilator in newly-diagnosed COPD patients in real-
life clinical practice.
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objeCtives: Tiotropium (tio) is a well-established bronchodilator, LAMA (long-acting 
anticholinergic), for the treatment of moderate to very severe COPD. Clinical evidence 
from the SPARK trial suggests that tio is superior to glycopyrronium (gly) in prevent-
ing severe exacerbations. This study assessed the cost-effectiveness of tio versus gly 
making use of this new clinical evidence. Methods: A Markov cohort model was 
populated with efficacy data from the UPLIFT and SPARK trials and cost and epidemio-
logical data relevant for each country. Treatment efficacy was modelled as improve-
ments in lung function, quality of life and as a lowering of the risk of exacerbations. 
The two interventions were assumed to be equally efficacious in terms of overall 
lung function, FEV1 (GLOW2 and SPARK trials). The relative efficacy of preventing 
exacerbations differed based on data from SPARK. Outcomes were simulated over an 
approximate life time horizon of 35 years, starting from an age of 65 years. Results: 
The base case analysis showed that patients treated with tio gained CAN: 0.23, SWE: 
0.24, UK: 0.25, QALYs compared to gly at an incremental cost of -955 (C$), 3,224 (SEK), 
-164 (£). For CAN and UK the analysis found tio to be dominating gly, while the Swedish 
analysis showed a cost per QALY gained of SEK 13,621. The results were mainly driven 
by the relative risk of severe exacerbations found in SPARK (RR: 1.43 CI 1.05-1.97, 
P 0.025). ConClusions: The results from this study show that tio adds benefits 
and savings in terms of QALYs and costs compared to gly monotherapy in high-risk 
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objeCtives: To present simple, objective, and customizable cost estimation formu-
las to compare per-attack treatment costs of four recently FDA-approved Hereditary 
Angioedema (HAE) products. Methods: Products developed for small orphan 
disease populations such as hereditary angioedema (HAE) are predictably costly. 
Comparing treatment costs among new HAE therapies is complicated by differences 
in dosing recommendations and re-dosing probabilities. We propose a simple cost 
estimation formula that factors in the non-static variables of body weight and re-
dosing likelihood per attack based on official prescribing recommendations and 
published clinical study data. Other administrative or indirect costs were not fac-
tored into the formulas. Results: Formulas were developed that allow insertion 
of local acquisition costs for any of the HAE products, according to the quantity of 
vials or syringes required for initial dosing. A weighted percentage of the cost of the 
initial dose was added to determine the total cost, factoring in the anticipated need 
for re-dosing. For products having more than one published re-dosing frequency, 
the lowest reported frequency was used as a conservative approach. Specific cost 
estimation formulas address three theoretical patient weight categories: ≤ 40 kg (to 
reflect small adults or pediatric patients), a standard 75 kg adult, and obese patients 
weighing between 100-125 kg. ConClusions: While therapy choices in HAE should 
be primarily driven by clinical factors and patient preferences, cost of treatment can 
be an important consideration if multiple options are considered equally appropri-
ate. The formulas presented provide a simple, objective means of quickly comparing 
direct product costs for treating an HAE attack using local pricing figures.
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objeCtives: Community-acquired pneumonia (CAP) is a leading cause of hospi-
talization in the US and is associated with substantial healthcare costs. The most 
commonly administered regimen for hospitalized patients, guideline-indicated intra-
venous azithromycin 500mg/ceftriaxone 1g (azi/ceft), is not available in identical oral 
formulation, requiring patients to switch regimen and potentially class when suffi-
ciently improved for oral treatment (oral switch). The incremental cost and resource 
utilization associated with this requirement has not been fully characterized. This 
study characterizes the incremental burden of a regimen lacking identical all-oral 
formulation. Methods: Inpatient stay data from the Truven Health Marketscan® 
Hospital Drug Database were used in this analysis. CAP inpatients treated with azi/
ceft were compared to those treated with intravenous levofloxacin 750mg (levo, a 
fluoroquinolone), the most commonly used regimen with an all-oral option. As previ-
ous studies have shown higher adverse event (AE) rates in fluoroquinolone patients, 
only patients (azi/ceft or levo) who remained on their treatment until oral switch 
were studied. Total charges, length of stay (LOS), and length of IV treatment (LOIV) 
were compared using multivariate regression models controlling for observed patient 
characteristics. Results: In the sample (N= 33,284), predicted average charges for azi/
ceft patients were $3,535 greater than charges for levo patients, with increased LOS 
of 0.33 days and LOIV of 0.65 days (all p< 0.0001). 28.3% of azi/ceft patients added an 
additional treatment class, versus 5.1% of levo patients. Characteristic comparisons 
showed that azi/ceft patients were older (66.4 vs. 64.7 years), but similar in health 
index (1.49 vs. 1.45) and AE rate (35.3% vs. 35.8%). ConClusions: Use of azi/ceft, the 
most common antibiotic regimen for hospitalized CAP patients but one that lacks 
an identical all-oral formulation, is associated with increased LOIV, LOS and cost. 
Efficacious alternatives with similar (or better) adverse event profiles and an all-oral 
formulation may yield cost and resource use savings.
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objeCtives: Chronic Obstructive Pulmonary Disease (COPD) is a main worldwide 
cause of morbidity and mortality. COPD prevalence in 40 years or older people is 7.8% 
in Mexico City. However, there is no information about direct cost of COPD patients 
in Mexico. This study estimated direct costs of COPD from patient perspective in a 
third level hospital. Methods: We conducted an interview at each visit by patients 
from august 2013 to July 2014 in a third level hospital. The diagnosis was carried out 
by a pulmonologist according to GOLD criteria. Information about direct and indirect 
costs was collected. Mean (SD) of annual total cost, medical consultation, clinical test, 
drugs, oxygen, transportation, gasoline and food were estimated for outpatients with 
at least one year of diagnosis and stratifying by severity. Costs were transformed in 
US Dollars of 2014. Results: We interviewed 482 outpatients. Patients were classified 
as: mild (n= 36), moderate (n= 137), severe (n= 76) and very severe (n= 233). Mean (SD) 
of age and diagnostic time were 72.4 (9.1) and 5.8 (4.2) years, respectively; and 257 
(53.2%) were men. Annual total costs for mild, moderate, severe and very severe were 
$915.3, $1214.3, $1382.6 and $1595.1, respectively. Drugs (74.0%), oxygen (19.5%) and 
transportation (1.8%) were the main categories of total costs. Less than 9% of patients 
can afford oxygen. ConClusions: According to total cost, severity is positively corre-
lated with the amount of out-of-pocket expenses. Oxygen is accessible to few patients.
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